- Details
- Description
Packaging Size:
1 vial × 2.4 mL
Strength:
120 mg / 2.4 mL (50 mg/mL)
Composition:
Durvalumab 120 mg; excipients include histidine, histidine hydrochloride monohydrate, trehalose dihydrate, polysorbate 80, and water for injection
Treatment:
Immunotherapy used for certain lung cancers, bladder/urothelial cancer, hepatocellular carcinoma, biliary tract cancer, and other approved cancer indications, depending on the treatment regimen.
Form:
Concentrate for solution for IV infusion
Brand:
Imfinzi
Quantity Unit:
Vial
Manufacturer:
AstraZeneca AB, Sweden
Imfinzi 120 mg / 2.4 mL (Durvalumab 120 mg) is an intravenous immunotherapy medicine used to treat certain types of cancer. Its active ingredient, durvalumab, is a monoclonal antibody and PD-L1 immune checkpoint inhibitor that helps restore the immune system’s ability to recognize and destroy cancer cells. It is used in the treatment of several cancers, including certain types of lung cancer, liver cancer, and biliary tract cancer, depending on the approved indication and treatment regimen. Imfinzi is administered by IV infusion under the supervision of a qualified healthcare professional.
Note: Imfinzi 120 mg is a single-dose vial for intravenous infusion after dilution and is a prescription oncology medicine.
